Immune checkpoint inhibitors as a neoadjuvant/adjuvant treatment of muscle-invasive bladder cancer: a systematic review
B Barone, A Calogero, L Scafuri, M Ferro, G Lucarelli… - Cancers, 2022 - mdpi.com
Simple Summary Bladder cancer is the ninth most common cancer worldwide. Immune
checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral …
checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral …
Checkpoint inhibitors in urothelial carcinoma—future directions and biomarker selection
Context Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …
[HTML][HTML] Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab),
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …
[HTML][HTML] Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
Abstract Introduction Immune checkpoint inhibitors (ICIs) have proved to be an effective
treatment for up to 40% of muscle-invasive bladder cancer (MIBC), but there is still a need …
treatment for up to 40% of muscle-invasive bladder cancer (MIBC), but there is still a need …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - Wiley Online Library
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
Abstract Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …
m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer
ZH Feng, YP Liang, JJ Cen, HH Yao, HS Lin… - Journal of Translational …, 2022 - Springer
Abstract Background N6-methyladenosine (m6A) related long noncoding RNAs (lncRNAs)
may have prognostic value in bladder cancer for their key role in tumorigenesis and innate …
may have prognostic value in bladder cancer for their key role in tumorigenesis and innate …
Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder
Context Immune therapy has emerged as a powerful treatment of metastatic urothelial
carcinoma. Over 20 ongoing studies are exploring this strategy in the neoadjuvant setting in …
carcinoma. Over 20 ongoing studies are exploring this strategy in the neoadjuvant setting in …
Evolution of urothelial bladder cancer in the context of molecular classifications
M Minoli, M Kiener, GN Thalmann… - International journal of …, 2020 - mdpi.com
Bladder cancer is a heterogeneous disease that is not depicted by current classification
systems. It was originally classified into non-muscle invasive and muscle invasive. However …
systems. It was originally classified into non-muscle invasive and muscle invasive. However …